Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.

Eugen TauschViktor LjungströmAndreas AgathangelidisMarc ZapatkaLydia ScarfòBilly Michael Chelliah JebarajDeyan Yordanov YosifovAnnika MüllerVeerendra MunugalavadlaJeremiah D DegenhardtPaolo GhiaRichard RosenquistStephan Stilgenbauer

Published in: Blood (2022)

Keyphrases

signaling pathway
pi k akt
cell proliferation
chronic lymphocytic leukemia
poor prognosis
binding protein
oxidative stress